Neurology Today: Sulthiame, a carbonic anhydrase inhibitor, lowered obstructive sleep apnea by more than 20 events per hour, one of the most notable declines observed in a drug trial for OSA.

The trial demonstrates that “sleep apnea may be treated pharmacologically, and sulthiame provides a strategy to be further evaluated for this indication,” the study’s lead author, Jan Hedner MD, PhD, a professor of respiratory medicine at Sahlgrenska University Hospital, a part of the University of Gothenburg in Sweden, told Neurology Today.

Dr. Hedner told Neurology Today that the new study has multiple strengths. In addition to being a randomized controlled trial, its advantages included stringent evaluation using state-of-the-art analysis equipment, a dose-finding design, and therapeutic drug monitoring.